Imunon (DB:CBO) - Hisse Senedi Fiyatı, Haberler ve Analizler

CBO Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Imunon, Inc. kanser ve bulaşıcı hastalıkları tedavi etmek için immünoterapiler ve aşılar geliştirmektedir. Daha fazla detay

CBO temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 22% oranında düşmesi öngörülüyor

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

+ 3 daha fazla risk

Imunon, Inc. Rakipler

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

4SC

DB:VSC

€49.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Imunon
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.66
52 Haftanın En Yüksek Seviyesi	US$3.70
52 Haftanın En Düşük Seviyesi	US$0.44
Beta	2.13
11 Aylık Değişim	-24.57%
3 Aylık Değişim	-40.00%
1 Yıllık Değişim	-6.38%
33 Yıllık Değişim	-93.02%
5 Yıllık Değişim	-96.42%
Halka arzdan bu yana değişim	-99.94%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	CBO	DE Biotechs	DE Pazar
7D	1.5%	-0.7%	-0.02%
1Y	-6.4%	-17.2%	8.2%

Getiri vs. Endüstri: CBO geçen yıl % -17.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: CBO geçen yıl % 8.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CBO's price volatile compared to industry and market?
CBO volatility
CBO Average Weekly Movement	9.5%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: CBO hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CBO 'nin haftalık oynaklığı son bir yılda 35% dan 10% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1982	33	Stacy Lindborg	imunon.com

Klinik aşamada bir biyoteknoloji şirketi olan Imunon, Inc. kanser ve bulaşıcı hastalıkları tedavi etmek için immünoterapiler ve aşılar geliştirmektedir. Şirketin lider klinik programı IMNN-001, yumurtalık kanserinin lokalize tedavisi için DNA bazlı bir immünoterapi olup Faz II klinik geliştirme aşamasındadır. Klinik öncesi aşamadaki ürünleri arasında bir COVID-19 güçlendirici aşısı olan IMNN-101; Lassa virüsünün tedavisi için IMNN-102; ve melanomda Trp2 tümör ilişkili antijen kanser aşısı olan IMNN-201 bulunmaktadır.

Imunon, Inc. Temel Bilgiler Özeti

Imunon'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CBO temel i̇stati̇sti̇kler
Piyasa değeri	€9.65m
Kazançlar(TTM)	-€18.68m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.6x

F/K Oranı

CBO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CBO gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$1.67m
Brüt Kâr	-US$1.67m
Diğer Giderler	US$17.78m
Kazançlar	-US$19.45m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.34
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

CBO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CBO Stoklara Genel Bakış

Risk Analizi

Imunon, Inc. Rakipler

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

DB:VSC

€49.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Recent updates

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020)

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform